Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Cabozantinib + Nivolumab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cabozantinib Cometriq Cabometyx|Cabozantinib-s-malate|XL184 AXL Inhibitor 30 FLT3 Inhibitor 66 KIT Inhibitor 57 MET Inhibitor 59 RET Inhibitor 52 ROS1 Inhibitor 20 VEGFR2 Inhibitor 37 Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov).
Nivolumab Opdivo MDX-1106|BMS-936558 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (UC) , esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) for melanoma, renal cell carcinoma (RCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy for PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy for metastatic or recurrent NSCLC without EGFR or ALK alterations, with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, with Cabometyx (cabozantinib) for advanced RCC, with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma, and with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic UC (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06364631 Phase III Cabozantinib + Nivolumab Ipilimumab + Nivolumab Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab CARE1 Pragmatic Clinical Trial (CARE1) Recruiting FRA 0
NCT03141177 Phase III Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) Active, not recruiting USA | ITA | GBR | ESP | DEU | AUS 12
NCT03937219 Phase III Cabozantinib + Nivolumab Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT05361720 Phase II Cabozantinib + Nivolumab Ipilimumab + Nivolumab Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Recruiting USA 0
NCT05502315 Phase II Cabozantinib + Nivolumab Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY) Recruiting USA 0
NCT03367741 Phase II Cabozantinib + Nivolumab Nivolumab Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer Active, not recruiting USA | CAN 0
NCT05136196 Phase II Cabozantinib + Nivolumab BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Recruiting USA 0
NCT04963283 Phase II Cabozantinib + Nivolumab Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Active, not recruiting USA 0
NCT06132945 Phase I Cabozantinib + Nivolumab A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain Recruiting USA 0
NCT05931393 Phase II Cabozantinib + Nivolumab Cabozantinib Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC) Recruiting USA 0
NCT02496208 Phase I Ipilimumab Cabozantinib + Nivolumab Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Active, not recruiting USA 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT03299946 Phase I Cabozantinib + Nivolumab Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) Completed USA 0
NCT04339738 Phase II Cabozantinib + Nivolumab Nivolumab + Paclitaxel Paclitaxel Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma Active, not recruiting USA 1
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Completed USA 0
NCT04197310 Phase II Cabozantinib + Nivolumab Cabozantinib and Nivolumab for Carcinoid Tumors Completed USA 0
NCT03316586 Phase II Cabozantinib + Nivolumab A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Completed USA 0
NCT05111574 Phase II Nivolumab Cabozantinib + Nivolumab Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Recruiting USA | CAN 0
NCT04310007 Phase II Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04091750 Phase II Cabozantinib + Ipilimumab + Nivolumab Cabozantinib + Nivolumab Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma Suspended USA 0
NCT05327686 Phase II Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab Ipilimumab + Nivolumab Avelumab + Axitinib Cabozantinib + Nivolumab Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI) Recruiting USA 0
NCT03866382 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting USA 1
NCT04151563 Phase Ib/II Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy Withdrawn USA | NLD | BEL 7
NCT04322955 Phase II Cabozantinib + Nivolumab CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK) Recruiting USA 0
NCT05039736 Phase II Cabozantinib + Nivolumab A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy Withdrawn 0
NCT03793166 Phase III Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Recruiting USA 1
NCT03635892 Phase II Cabozantinib + Nivolumab A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma Active, not recruiting USA 0
NCT05122546 Phase I Cabozantinib + Nivolumab Cabozantinib + CBM588 + Nivolumab CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Active, not recruiting USA 0


Additional content available in CKB BOOST